Abstract
No public abstract is available from the verified source records.
Lisa Vermunt, Nicholas R Barthélemy, Inge M W Verberk, Suzanne E Schindler
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Blood-based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals within specialized care settings: a systematic review and meta-analysis
10.1002/alz.70828 · 2025
Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
10.1016/s1474-4422(25)00227-3 · 2025
Lecanemab: appropriate use recommendations
10.14283/jpad.2023.30 · 2023
Donanemab: appropriate use recommendations
10.1016/j.tjpad.2025.100150 · 2025
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
10.1002/alz.13859 · 2024
Alzheimer disease as a clinical-biological construct—an International Working Group Recommendation
10.1001/jamaneurol.2024.3770 · 2024
Acceptable performance of blood biomarker tests of amyloid pathology—recommendations from the Global CEO Initiative on Alzheimer's Disease
10.1038/s41582-024-00977-5 · 2024
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
10.1038/s41573-025-01165-w · 2025
Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
10.1038/s43587-023-00550-7 · 2024
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
10.1016/s1474-4422(23)00405-2 · 2024
Future Directions in Alzheimer's Disease and Related Disorders 2. Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy
10.1016/s1474-4422(26)00285-1 · 2026
Future Directions in Alzheimer's Disease and Related Disorders 3. Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change
10.1016/s1474-4422(26)00248-6 · 2026
Blood biomarkers to detect Alzheimer disease in primary care and secondary care
10.1001/jama.2024.13855 · 2024
Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
10.1002/alz.14150 · 2024
Biofluid biomarkers in Alzheimer's disease and other neurodegenerative dementias
10.1038/s41586-025-10018-w · 2026
Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderly
10.1186/s13195-025-01925-1 · 2025
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
10.1002/alz.14088 · 2024
Detection of Alzheimer neuropathology in Alzheimer and non-Alzheimer clinical syndromes with blood-based biomarkers
10.1001/jamaneurol.2024.5017 · 2025
Performance of plasma p-tau217 and NfL in an unselected memory clinic setting
2024
Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
10.1038/s41467-021-23746-0 · 2021
Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures
10.1038/s41591-021-01348-z · 2021
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
10.1001/jama.2023.13239 · 2023
Clinical use of biomarkers in the era of Alzheimer's disease treatments
10.1002/alz.14201 · 2025
Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability
10.1038/s43587-024-00731-y · 2024
Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings
10.1002/alz.70535 · 2025
Head-to-head comparison of leading blood tests for Alzheimer's disease pathology
10.1002/alz.14315 · 2024
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
10.1038/s41573-025-01165-w · 2025
Primary age-related tauopathy (PART): a common pathology associated with human aging
10.1007/s00401-014-1349-0 · 2014
Frontotemporal dementia
10.1016/s1474-4422(05)70223-4 · 2005
Tau protein and frontotemporal dementias
2021
The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies
10.1007/s00401-020-02157-3 · 2020
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
10.1093/brain/awz099 · 2019
Chronic effects of inflammation on tauopathies
10.1016/s1474-4422(23)00038-8 · 2023
Role of neuroinflammation in neurodegeneration development
10.1038/s41392-023-01486-5 · 2023
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
10.1038/s41582-020-00435-y · 2021
Ageing as a risk factor for neurodegenerative disease
10.1038/s41582-019-0244-7 · 2019
Polygenic risk scores in neurodegenerative diseases: a review
10.1007/s40142-019-0158-0 · 2019
Association of plasma and cerebrospinal fluid Alzheimer disease biomarkers with race and the role of genetic ancestry, vascular comorbidities, and neighborhood factors
10.1001/jamanetworkopen.2022.35068 · 2022
Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases
10.3389/fncel.2015.00124 · 2015
The global burden of neurological disorders: translating evidence into policy
10.1016/s1474-4422(19)30411-9 · 2020
Evidence that minocycline treatment confounds the interpretation of neurofilament as a biomarker
10.1093/braincomms/fcaf175 · doi-reference
Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration
10.1093/brain/awx339 · doi-reference
Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis
10.1038/s41591-026-04272-2 · doi-reference
ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression
10.1002/acn3.70001 · doi-reference
Clinical validation of plasma p-217tau in neurological diseases
10.1002/acn3.70359 · doi-reference
Lecanemab in early Alzheimer's disease
10.1056/nejmoa2212948 · doi-reference
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
10.15252/emmm.202114022 · doi-reference
Early Alzheimer's Disease with frequent neuritic plaques harbors neocortical tau seeds distinct from primary age-related tauopathy
10.1038/s41467-025-56469-7 · doi-reference
Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
10.1186/s40478-021-01307-2 · doi-reference
Tau kinetics in neurons and the human central nervous system
10.1016/j.neuron.2018.04.035 · doi-reference
Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein
10.1126/scitranslmed.3006446 · doi-reference
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study
10.1016/s1474-4422(21)00214-3 · doi-reference
Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease
10.1002/ana.1054 · doi-reference
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease
10.1038/s41591-023-02443-z · doi-reference
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
10.1186/s13195-024-01456-1 · doi-reference
Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer's disease
10.1186/s13024-025-00822-3 · doi-reference
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay
10.1002/alz.13658 · doi-reference
Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease
10.1002/alz.13431 · doi-reference
Response to Xing et al. Post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database
10.1186/s13195-025-01735-5 · doi-reference
Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance
10.1186/s13195-025-01699-6 · doi-reference
Dementia registries around the globe and their applications: a systematic review
10.1016/j.jalz.2017.04.005 · doi-reference
Alzheimer's Association launches ALZ-NET: A long-term data collection and sharing network for new treatments
10.1002/alz.12782 · doi-reference
Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots—a new collection method for remote settings
10.1002/alz.13697 · doi-reference
Plasma biomarkers for cerebral amyloid angiopathy and implications for amyloid-related imaging abnormalities: a comprehensive review
10.3390/jcm14041070 · doi-reference
Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study
10.1002/alz.71231 · doi-reference
Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial
10.1001/jamaneurol.2022.3392 · doi-reference
A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia
10.1038/s41591-026-04303-y · doi-reference
A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease
10.1038/s41591-025-03565-2 · doi-reference
Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study
10.1016/s1474-4422(25)00350-3 · doi-reference
Interpreting biomarker results in individual patients with mild cognitive impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project
10.1001/jamaneurol.2017.2712 · doi-reference
Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project
10.1186/s13195-019-0487-y · doi-reference
Limited generalizability and high risk of bias in multivariable models predicting conversion risk from mild cognitive impairment to dementia: a systematic review
10.1002/alz.70069 · doi-reference
CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients
10.1186/s13195-025-01799-3 · doi-reference
Identification of distinct and shared biomarker panels in different manifestations of cerebral small-vessel disease through proteomic profiling
10.1038/s43587-026-01081-7 · doi-reference
Association of CSF α-synuclein seed amplification assay positivity with disease progression and cognitive decline: a longitudinal Alzheimer's Disease Neuroimaging Initiative study
10.1002/alz.14276 · doi-reference
Predicting cognitive decline in amyloid-positive patients with mild cognitive impairment or mild dementia
10.1212/wnl.0000000000209605 · doi-reference
Prediction models for conversion from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis
10.3389/fnagi.2022.840386 · doi-reference
Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis
10.1186/s13195-018-0459-7 · doi-reference
Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype
10.1016/j.jalz.2019.04.001 · doi-reference
Multimorbidity and risk of dementia: a systematic review and meta-analysis of longitudinal cohort studies
10.1016/j.tjpad.2025.100164 · doi-reference